The drugmaker is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy ...

The market for weight loss drugs is white-hot, and competition is heating up fast. This Danish company is already facing a ...

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

Novo Nordisk shares rose by more than 5% after the Danish weight-loss drug maker said the Food and Drug Administration accepted a new drug application for a pill form of its popular Wegovy injection.

Novo Nordisk has teamed up with Hims & Hers Health, LifeMD and Ro for cash-paying patients to access Wegovy injection 2.4 mg ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

NVO's first-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially ...

Danish drugmaker Novo Nordisk has announced that it is expanding patient access to Wegovy (semaglutide) injection 2.4 mg in ...

Using the latest data and perspectives, an international expert panel releases updated recommendations for optimal insulin ...

Keeping up with the GLP-1 area is a full-time job by itself. First off, you have the recent development that these drugs are ...